NSCLC subtype prediction using cytologic fluid specimens from needle aspiration biopsies.

Area of Science:

• Oncology
• Diagnostic Imaging
• Biochemistry

Background:

• Non-small cell lung cancer (NSCLC) diagnosis and subtyping are critical for treatment.
• Current methods for subtyping NSCLC can be invasive or lack specificity.
• Tumor markers in cytologic fluids (CF) offer a potential minimally invasive approach.

Purpose of the Study:

• To evaluate the diagnostic utility of tumor marker concentrations in CF for subtyping NSCLC.
• To assess the correlation between (18)F-FDG uptake and serum/CF tumor marker levels.
• To determine the accuracy of specific tumor markers in differentiating adenocarcinoma from squamous cell carcinoma (SCC).

Main Methods:

• Prospective study of 88 patients with NSCLC (adenocarcinoma or SCC).
• Measurement of Cytokeratin-19 fragment (CYFRA 21-1), carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCCA) in CF and serum.
• Correlation analysis with (18)F-FDG uptake and NSCLC subtype.

Main Results:

• Multivariate analysis identified higher CF and serum SCCA levels and smoking status as predictors of SCC.
• Cytologic fluid SCCA demonstrated the highest accuracy (83%) in distinguishing SCC from adenocarcinoma.
• Adequate tumor marker levels were found in CF samples from routine needle aspiration biopsies.

Conclusions:

• Cytologic fluid tumor markers, particularly CF SCCA, are valuable for subtyping NSCLC.
• CF SCCA offers high diagnostic accuracy in differentiating squamous cell carcinoma from adenocarcinoma.
• Routine cytologic fluid analysis can provide sufficient tumor marker data for NSCLC subtyping.